Wenxi Tang

1.8k total citations
108 papers, 1.2k citations indexed

About

Wenxi Tang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Economics and Econometrics. According to data from OpenAlex, Wenxi Tang has authored 108 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 27 papers in Oncology and 25 papers in Economics and Econometrics. Recurrent topics in Wenxi Tang's work include Health Systems, Economic Evaluations, Quality of Life (16 papers), Healthcare Systems and Reforms (13 papers) and Lung Cancer Treatments and Mutations (13 papers). Wenxi Tang is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (16 papers), Healthcare Systems and Reforms (13 papers) and Lung Cancer Treatments and Mutations (13 papers). Wenxi Tang collaborates with scholars based in China, United States and United Kingdom. Wenxi Tang's co-authors include Liang Zhang, Mingye Zhao, Zheng‐Yi Zhou, Yan Zhang, Keith A. Betts, Eric Q. Wu, Fan Mu, J. Michael Woolley, Ting Ye and Gregory A. Otterson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Immunology.

In The Last Decade

Wenxi Tang

97 papers receiving 1.1k citations

Peers

Wenxi Tang

PRM

ONCOL

GHP

Steven T. Fleming United States

Catherine G. Lam United States

Asem Mansour Jordan

Fernando Alarid‐Escudero United States

Yafang Huang China

Pengxiang Li United States

Eva Karlsson Sweden

Ágnes Benedict United States

Verna Vanderpuye Ghana

Paul Carter United Kingdom

Steven T. Fleming United States

Wenxi Tang

145 ×0.3

PRM

561 ×1.9

ONCOL

354 ×1.7

GHP

174 ×0.9

483 ×2.6

Citations per year, relative to Wenxi Tang Wenxi Tang (= 1×) peers Steven T. Fleming

Countries citing papers authored by Wenxi Tang

Since Specialization

Citations

This map shows the geographic impact of Wenxi Tang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wenxi Tang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wenxi Tang more than expected).

Fields of papers citing papers by Wenxi Tang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wenxi Tang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wenxi Tang. The network helps show where Wenxi Tang may publish in the future.

Co-authorship network of co-authors of Wenxi Tang

This figure shows the co-authorship network connecting the top 25 collaborators of Wenxi Tang. A scholar is included among the top collaborators of Wenxi Tang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wenxi Tang. Wenxi Tang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Xu, Lei, et al.. (2025). Cost–benefit analysis of universal screening for HCV infection in China: a Markov modelling study. BMC Health Services Research. 25(1). 1230–1230.

Zhao, Mingye, et al.. (2025). Racial, ethnic, sex, and age representation in clinical trials of radiopharmaceutical tumor therapy: a systematic review and meta-analysis. BMC Cancer. 25(1). 1092–1092.

Spann, Nathanael J., Wenxi Tang, Fenghua Zeng, et al.. (2025). Genetic variation in the activity of a TREM2–p53 signaling axis determines oxygen-induced lung injury. Nature Immunology. 26(8). 1287–1298.

Li, Yuan, et al.. (2024). Economic evaluation of NALIRIFOX vs. nab-paclitaxel and gemcitabine regimens for first-line treatment of metastatic pancreatic ductal adenocarcinoma from U.S. perspective. Cost Effectiveness and Resource Allocation. 22(1). 70–70. 2 indexed citations

Yin, Yue, et al.. (2024). Development and validation of the Chinese patient-centered integrated care scale. BMC Health Services Research. 24(1). 1668–1668. 1 indexed citations

Zhao, Mingye, et al.. (2024). A network meta-analysis of efficacy and safety for first-line and second/further-line therapies in postmenopausal women with hormone receptor-positive, HER2-negative, advanced breast cancer. BMC Medicine. 22(1). 13–13. 10 indexed citations

Zhao, Mingye, et al.. (2024). Impacts of systemic treatments on health-related quality of life for patients with metastatic colorectal cancer: a systematic review and network meta-analysis. BMC Cancer. 24(1). 188–188. 5 indexed citations

Zhao, Mingye, et al.. (2023). Effectiveness and cost-effectiveness analysis of 11 treatment paths, seven first-line and three second-line treatments for Chinese patients with advanced wild-type squamous non-small cell lung cancer: A sequential model. Frontiers in Public Health. 11. 1051484–1051484. 10 indexed citations

Zhao, Mingye, et al.. (2023). Impact of Extrapolation Model Choices on the Structural Uncertainty in Economic Evaluations for Cancer Immunotherapy: A Case Study of Checkmate 067. PharmacoEconomics - Open. 7(3). 383–392. 5 indexed citations

10.

Avari, Parizad, Wenxi Tang, Narvada Jugnee, et al.. (2023). The Accuracy of Continuous Glucose Sensors in People with Diabetes Undergoing Hemodialysis (ALPHA Study). Diabetes Technology & Therapeutics. 25(7). 447–456. 16 indexed citations

11.

Zhao, Mingye, et al.. (2022). Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. Frontiers in Public Health. 10. 869960–869960. 33 indexed citations

12.

Stenehjem, David D., Solomon J. Lubinga, Keith A. Betts, et al.. (2021). Treatment Patterns in Patients with Metastatic Non-Small-Cell Lung Cancer in the Era of Immunotherapy. Future Oncology. 17(22). 2940–2949. 14 indexed citations

13.

Ma, Yunsheng, et al.. (2021). PIN26 Lifetime cost estimation of human papillomavirus related diseases in China: a modelling study using real-world data. Value in Health. 24. S110–S110. 1 indexed citations

14.

Griffin, James D., et al.. (2019). PCN168 ECONOMIC BURDEN OF RELAPSE AFTER HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH ACUTE MYELOID LEUKEMIA (AML): A RETROSPECTIVE CLAIMS-BASED ANALYSIS. Value in Health. 22. S468–S468. 1 indexed citations

15.

Chen, Kristina, et al.. (2018). Identifying a subpopulation with higher likelihoods of early response to treatment in a heterogeneous rare disease: a post hoc study of response to teduglutide for short bowel syndrome. Therapeutics and Clinical Risk Management. Volume 14. 1267–1277. 18 indexed citations

16.

Tang, Wenxi, et al.. (2018). The Relationship Between Medical Insurance Coverage and Medication Payments in The US from 1997 to 2015. Value in Health. 21. S90–S90. 1 indexed citations

17.

Zhang, Yan, Wenxi Tang, & Liang Zhang. (2017). What Impact Does Behavior of Doctors and Patients on Service Integration of Multi-institutional Readmission cross Township—county Hospitals in Rural China. International Journal of Integrated Care. 17(3). 53–53. 1 indexed citations

18.

Migden, Michael R., et al.. (2017). Burden and treatment patterns of advanced basal cell carcinoma among commercially insured patients in a United States database from 2010 to 2014. Journal of the American Academy of Dermatology. 77(1). 55–62.e3. 5 indexed citations

19.

Tang, Wenxi, Lai Wei, & Liang Zhang. (2017). Analysing a Chinese Regional Integrated Healthcare Organisation Reform Failure using a Complex Adaptive System Approach. International Journal of Integrated Care. 17(2). 3–3. 11 indexed citations

20.

Gu, Weijun, et al.. (2012). Diabetic ketoacidosis at diagnosis influences complete remission after treatment of hematopoietic stem cell transplantation in adolescents with type 1 diabetes. 15th International & 14th European Congress of Endocrinology. 29. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact